7 active not recruiting. 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Active not recruiting 7 |
Follow Eczema: new trials by email Literature Review of Eczema trials Research Report on Eczema
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis BFB759, Placebo - Atopic Dermatitis (AD) | Phase 2 | Active not recruiting | Bluefin Biomedicine, Inc. | 225 | 2025-07-15 | 2026-07-30 |
| ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis ATI-045, Placebo - Atopic Dermatitis, Atopic | Phase 2 | Active not recruiting | Aclaris Therapeutics, Inc. | 110 | 2025-05-30 | 2026-09-29 |
| A Study of Barzolvolimab in Patients With Atopic Dermatitis Barzolvolimab, Matching placebo - Atopic Dermatitis | Phase 2 | Active not recruiting | Celldex Therapeutics | 131 | 2024-12-18 | 2026-08-11 |
| A Study of TAVO101 in Atopic Dermatitis Patients TAVO101 - Atopic Dermatitis | Phase 2 | Active not recruiting | Tavotek Biotherapeutics | 20 | 2024-03-15 | 2024-11-18 |
| A Herbal Compound for Eczema ZAX.1400.EC.02, Placebo - Eczema, Atopic Dermatitis | Phase 2 | Active not recruiting | Fasa University of Medical Sciences | 110 | 2023-10-01 | 2025-01-06 |
| A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis PF-07275315, PF-07264660, Placebo - Atopic Dermatitis | Phase 2 | Active not recruiting | Pfizer | 507 | 2023-08-22 | 2026-10-23 |
| Seal, Stopping Eczema and Allergy Study Tri-lipid skin barrier cream (Epiceram), Fluticasone propionate Cream 0.05%, Standard of Care - Eczema, Infantile, Eczema | Phase 2 | Active not recruiting | Kari Nadeau, MD, PhD | 398 | 2021-06-30 | 2026-02-27 |
Dermatitis, Atopic (7) · Dermatitis (2) · Food Hypersensitivity (1) · Inflammation (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (7) · Genetic Diseases, Inborn (7) · Hypersensitivity (7) · Hypersensitivity, Immediate (7) · Immune System Diseases (7) · Skin Diseases (7) · Skin Diseases, Eczematous (7) · Skin Diseases, Genetic (7) · Skin and Connective Tissue Diseases (7) · Dermatitis (5) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
EpiCeram (1) · Standard of Care (1)
Aclaris Therapeutics, Inc. (1) · Bluefin Biomedicine, Inc. (1) · Celldex Therapeutics (1) · Fasa University of Medical Sciences (1) · Kari Nadeau, MD, PhD (1) · Pfizer (1) · Tavotek Biotherapeutics (1)
United States (5) · Canada (3) · Australia (2) · Germany (2) · Poland (2) · Bulgaria (1) · China (1) · Czechia (1) · Iran (1) · Japan (1) · New Zealand (1) · Spain (1) · United Kingdom (1)
Kari Nadeau, MD, PhD (1) · Penelope Montgomery, MD (1)
2023 (1), U01AI147462 (1)